2020-10-19

1: Nageshappa S, Carromeu C, Trujillo CA, Mesci P, Espuny-Camacho I, Pasciuto E, 
Vanderhaeghen P, Verfaillie CM, Raitano S, Kumar A, Carvalho CM, Bagni C, Ramocki 
MB, Araujo BH, Torres LB, Lupski JR, Van Esch H, Muotri AR. Altered neuronal 
network and rescue in a human MECP2 duplication model. Mol Psychiatry. 2016 
Feb;21(2):178-88. doi: 10.1038/mp.2015.128. Epub 2015 Sep 8. PubMed PMID: 
26347316; PubMed Central PMCID: PMC4720528.

2: Victoriano AF, Imai K, Togami H, Ueno T, Asamitsu K, Suzuki T, Miyata N, 
Ochiai K, Okamoto T. Novel histone deacetylase inhibitor NCH-51 activates latent 
HIV-1 gene expression. FEBS Lett. 2011 Apr 6;585(7):1103-11. doi: 
10.1016/j.febslet.2011.03.017. Epub 2011 Mar 12. PubMed PMID: 21402072.

3: Sanda T, Okamoto T, Uchida Y, Nakagawa H, Iida S, Kayukawa S, Suzuki T, 
Oshizawa T, Suzuki T, Miyata N, Ueda R. Proteome analyses of the growth 
inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid 
malignant cells. Leukemia. 2007 Nov;21(11):2344-53. Epub 2007 Aug 9. PubMed PMID: 
17690692.

4: Suzuki T, Hisakawa S, Itoh Y, Maruyama S, Kurotaki M, Nakagawa H, Miyata N. 
Identification of a potent and stable antiproliferative agent by the prodrug 
formation of a thiolate histone deacetylase inhibitor. Bioorg Med Chem Lett. 2007 
Mar 15;17(6):1558-61. Epub 2007 Jan 13. PubMed PMID: 17257837.